FLT3 and acute lymphoblastic leukemia: Nevertheless, the evidence of the striking overexpression of FLT3 in KMT2A-r infant ALL and the preclinical data of FLT3 inhibition strategy efficacy in KMT2A-r ALL cells [130] has prompted clinical investigation of FLT3i also in KMT2A-r ALL.